Login to Your Account



Other News To Note


Monday, June 4, 2012
• Avanir Pharmaceuticals Inc., of Aliso Viejo, Calif., reported preliminary results from the PRISM patient registry to define pseudobulbar affect (PBA) prevalence and its quality-of-life impact, with results from the 3,647 patients with underlying neurologic conditions – Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis, Parkinson's disease, stroke and traumatic brain injury – showing that 37.3 percent had a positive screening score for PBA.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription